Dr. Chin is the former CMO, and current SVP, Clinical and Translational Science at Frequency Therapeutics and currently Bertarelli Professor of Translational Medical Science and Professor of Medicine Emeritus at Harvard Medical School. He previously served as CMO and Executive Vice President at PhRMA and Executive Dean for Research at Harvard Medical School, following a 10-year career at Eli Lilly, where he was most recently Senior Vice President for Discovery Research and Clinical Investigation. Prior to Lilly, he was Professor of Medicine and a Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School; Chief of the Division of Genetics and Senior Physician at Brigham and Women’s Hospital and Investigator, Howard Hughes Medical Institute. Dr. Chin is a world-renowned molecular endocrinologist who has received many awards for his research on the molecular mechanisms of nuclear receptor action on thyroid, estrogen, and other hormones. He serves on several scientific boards, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Child Health and Human Development (NICHD), Agency for Science, Technology and Research in Singapore, Rhythm Pharmaceuticals and Lobesity. He received an AB in Chemistry from Columbia College and M.D. from Harvard Medical School.